Overview

Reducing Chemoradiotherapy And Radiation With Targeted Immunotherapy in Children, Adolescents and Young Adults With Lymphoma

Status:
Recruiting

Trial end date:
2028-06-30

Target enrollment:
0

Participant gender:
All

Summary

The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

New York Medical College

Treatments:

Cytarabine
Etoposide

Criteria

Inclusion Criteria:

- Newly diagnosed patients with histologically or cytologically proven newly diagnosed
MB-NHL or cHL according to WHO Classification who meet the following criteria are
eligible:

COHORT I:

Burkitt lymphoma (ICD-O 9687/3) Burkitt-like lymphoma with 11q aberration (ICD-O 9687/3)
Diffuse large B-cell lymphoma, NOS (ICD-O 9680/3) High grade B-cell lymphoma (ICD-O 9680/3)

COHORT Ia: stage III with LDH ≥ 2 ULN OR stage IV (5-24% bone marrow lymphoma infiltration)
(GROUP B)61

COHORT Ib: any CNS involvement and/or BM involvement (≥ 25% lymphoma cells) (GROUP C)61 OR
patients with less than 20% tumor size reduction post chemotherapy with cyclophosphamide,
dexamethasone, vincristine (DOC Reduction for Cohort Ia).

COHORT II Classical Hodgkin lymphoma (ICD-O 9650/3, 9663/3, 9651/3, 9652/3, 9653/3)

COHORT IIa: stage I-IIA with bulky ± E, I-IIB no bulky ± E, IIIA ± E (INTERMEDIATE RISK)

COHORT IIb: stage IIB with bulky ± E, IIIA with bulky ± E, IIIB, IV (HIGH RISK)

- Adequate organ function

Exclusion Criteria:

- Primary mediastinal B-cell lymphoma (PMBL)

- T-cell/histiocyte-rich large B-cell lymphoma

- Gray zone lymphoma

- Follicular lymphoma

- Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)

- Posttransplant lymphoproliferative lymphoma (PTLD)